Shares Magazine
10,422.00p+184.00 (+1.79%)23 Dec 2024, 16:41
Jump to:
Astrazeneca PLC Fundamentals
| Company Name | Astrazeneca PLC | Last Updated | 2024-12-23 |
|---|---|---|---|
| Industry | Drug Manufacturers - General | Sector | Healthcare |
| Shares in Issue | 1.550 bn | Market Cap | £161.85 bn |
| PE Ratio | 31.41 | Dividend per Share | $2.88 |
| Dividend Yield | 2.28 | Dividend Cover | 1.32 |
| EPS | $3.81 | EPS Growth (%) | 0.64 |
| PEG | 0.70 | DPS Growth (%) | 0.0150 |
| Debt Ratio | 0.3008 | Debt Equity Ratio | 0.7366 |
| Asset Equity Ratio | 2.5713 | Cash Equity Ratio | 0.1208 |
| Quick Ratio | 0.6483 | Current Ratio | 0.93 |
| Price To Book Value | 4.9628 | ROCE | 0 |
Astrazeneca PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Interim | 2024-08-08 | 2024-09-09 | GBP | 0.7760 | |
| Prelim | 2024-02-22 | 2024-03-25 | GBP | 1.5600 | |
| Interim | 2023-08-10 | 2023-09-11 | GBP | 0.7180 | |
| Prelim | 2023-02-23 | 2023-03-27 | GBP | 1.6280 | |
| Interim | 2022-08-11 | 2022-09-12 | GBP | 0.7640 | |
| Prelim | 2022-02-24 | 2022-03-28 | GBP | 1.4530 |
Astrazeneca PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | $10.50 bn | $9.45 bn | $10.17 bn |
| Intangible Assets | $58.14 bn | $59.13 bn | $62.38 bn |
| Investments | $1.68 bn | $1.14 bn | $1.24 bn |
| Total Fixed Assets | $76.06 bn | $73.89 bn | $79.12 bn |
| Stocks | $5.42 bn | $4.70 bn | $8.98 bn |
| Debtors | $10.51 bn | $9.19 bn | $8.13 bn |
| Cash & Equivalents | $5.86 bn | $6.24 bn | $6.40 bn |
| Other Assets | $5.75 bn | $4.17 bn | $5.33 bn |
| Total Assets | $101.12 bn | $96.48 bn | $105.36 bn |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | $30.54 bn | $26.29 bn | $22.59 bn |
| Creditors after 1 year | $31.41 bn | $33.13 bn | $43.48 bn |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $61.95 bn | $59.42 bn | $66.08 bn |
| Net assets | $39.17 bn | $37.06 bn | $39.29 bn |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | $388.00 m | $387.00 m | $387.00 m |
| Share Premium | $35.34 bn | $35.31 bn | $35.28 bn |
| Profit / Loss | $6.90 bn | $2.50 bn | -$265.00 m |
| Other Equity | $39.14 bn | $37.04 bn | $39.27 bn |
| Preference & Minorities | $23.00 m | $21.00 m | $19.00 m |
| Total Capital Employed | $39.17 bn | $37.06 bn | $39.29 bn |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | $0.37 | $0.39 | $0.42 |
| Debt-to-Equity | $0.59 | $0.64 | $0.74 |
| Assets / Equity | 2.5713 | 2.5713 | 2.5713 |
| Cash / Equity | 0.1208 | 0.1208 | 0.1208 |
| EPS | $4.11 | $2.51 | -$0.60 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | $10.35 bn | $9.81 bn | $5.96 bn |
| Cashflow before financing | $3.78 bn | $2.98 bn | $9.61 bn |
| Increase in Cash | -$286.00 m | $25.00 m | -$1.45 bn |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | $45.81 bn | $44.35 bn | $37.42 bn |
| Cost of sales | $8.27 bn | $12.39 bn | $12.44 bn |
| Gross Profit | $37.54 bn | $31.96 bn | $24.98 bn |
| Operating Profit | $8.19 bn | $3.76 bn | $1.06 bn |
| Pre-Tax profit | $6.90 bn | $2.50 bn | -$265.00 m |
Astrazeneca PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory,cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales. |
| Latest Interim Date | 25 Jul 2024 |
| Latest Fiscal Year End Date | 8 Feb 2024 |
Astrazeneca PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2016-12-01 | Mr. Jean-Philippe Courtois | Non-Executive Director |
| 2010-11-16 | Ms. Michele J. Hooper | Non-Executive Director |
| 1995-04-11 | Sir Peter Leahy Bonfield CBE | Non-Executive Director |
| 2019-04-26 | Mr. Rudolph Harold Peter Markham | Non-Executive Director |
| 2024-02-20 | Ms. Sherilyn S. McCoy | Non-Executive Director |
| 2010-10-29 | Dr. Jane E Henney, M.D. | Non-Executive Director |
| 2019-03-07 | Mr. David R Brennan | Executive Director,Chief Executive Officer |
| 2024-02-20 | Dr. Andreas Rummelt | Non-Executive Director |
| 2009-10-30 | Mr. Bo Angelin | Non-Executive Director |
| 2000-12-22 | Ms. Erna Moller | Non-Executive Director |
| 2011-11-16 | Dr. Hakan L. Mogren | Non-Executive Director,Deputy Chairman |
| 2015-04-24 | Dr. John Silvester Varley | Non-Executive Director |
| 2011-08-09 | Sir Jonathan Richard Symonds CBE | Executive Director,Chief Financial Officer |
| 2024-02-20 | Mr. Leif Johansson | Non-Executive Director,Chairman |
| 2012-06-01 | Mr. Louis Schweitzer | Non-Executive Director,Chairman |
| 2022-02-22 | Mr. Marc Dunoyer | Executive Director,Chief Financial Officer |
| 2024-02-20 | Mr. Marcus Wallenberg | Non-Executive Director |
| 2024-11-15 | Mr. Michel Demare | Non-Executive Director,Chairman |
| 2024-11-15 | Mr. Pascal Soriot | Executive Director,Chief Executive Officer |
| 2024-11-13 | Mr. Philip A J Broadley | Non-Executive Director,Senior Independent Director |
| 2014-03-20 | Mr. Simon Jonathan Lowth | Executive Director,Chief Financial Officer |
| 2011-08-09 | Dr. John Simon Patterson, CBE | Executive Director |
| 2015-04-24 | Professor Dame Nancy Rothwell | Non-Executive Director |
| 2005-08-25 | Sir John Buchanan | Non-Executive Director |
| 2023-02-21 | Mr. Graham Andrew Chipchase, C.B.E. | Non-Executive Director,Senior independent Director |
| 2023-02-21 | Ms. Genevieve Berger | Non-Executive Director |
| 2017-11-13 | Dr. Bruce Burlington | Non-Executive Director |
| 2003-09-08 | Mr. Joe Jimenez | Non-Executive Director |
| 2019-03-05 | Baroness Shriti Vadera | Non-Executive Director |
| 2017-04-27 | Ms. Ann Cairns | Non-Executive Director |
| 2024-02-20 | Ms. Diana Layfield | Non-Executive Director |
| 2024-02-20 | Ms. Deborah DiSanzo | Non-Executive Director |
| 2024-02-20 | Ms. Anna Olive Magdelene Manz | Non-Executive Director |
| 2016-09-30 | Dr. Cornelia Bargmann | Non-Executive Director |
| 2024-02-20 | Professor Nazneen Rahman | Non-Executive Director |
| 2024-03-06 | Dr. Aradhana Sarin | Executive Director,Chief Financial Officer |
| 2024-11-20 | Professor Tony Mok | Non-Executive Director |
| 2024-02-20 | Dr. Euan Ashley | Non-Executive Director |
Astrazeneca PLC Contact Details
| Company Name | AstraZeneca PLC |
|---|---|
| Address | 2 Kingdom Street, London, W2 6BD |
| Telephone | +44 2076048000 |
| Website | https://www.astrazeneca.com |
Astrazeneca PLC Advisors
| Auditor | KPMG |
|---|---|
| Phone | +44 2073111000 |
| Fax | +44 2073113311 |
| Remuneration Consultant | Deloitte LLP |
|---|---|
| Phone | +44 2079363000 |
| Fax | +44 2075831198 |
| Financial PR Adviser | Finsbury |
|---|---|
| Phone | +44 2072513801 |
| Fax | +44 2073744133 |
| Bank | Citibank |
|---|---|
| Phone | +44 2075005500 |
| Bank | HSBC Bank PLC |
|---|
| Registrar | Equiniti Ltd. |
|---|---|
| Phone | +44 1214157082 |
| Solicitor | Freshfields Bruckhaus Deringer |
|---|---|
| Phone | +44 2079364000 |
| Fax | +44 2078327001 |
| Stockbroker | Goldman Sachs International |
|---|---|
| Phone | +44 2077741000 |
| Stockbroker | Morgan Stanley & Co International PLC |
|---|---|
| Phone | +44 2074258000 |
| Fax | +44 2074258990 |
| Auditor | KPMG AUDIT PLC |
|---|
| Auditor | KPMG LLP |
|---|---|
| Phone | +1 212 758-9700 |
| Fax | +1 212 758-9819 |
| Auditor | KPMG Klynveld Peat Marwick Goerdeler SA |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Ceres Power Holdings PLC | 171.44 | 3.96 |
| Direct Line Insurance Group PLC | 252.40 | 3.78 |
| Chrysalis Investments Limited | 105.40 | 3.74 |
| Airtel Africa PLC | 108.60 | 3.13 |
| Sthree PLC | 278.00 | 2.96 |
| Pantheon International PLC | 318.50 | 2.58 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Intercontinental Hotels Group PLC | 31.21 | -99.69 |
| Next PLC | 39.80 | -99.59 |
| Metro Bank Holdings PLC | 92.90 | -7.01 |
| Bridgepoint Group PLC | 345.60 | -4.27 |
| Moonpig Group PLC | 212.00 | -4.07 |
| Frasers Group PLC | 605.50 | -3.35 |